Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–25. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosd with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-3.
   PubMed Web of Science ®Google Scholar
• He S, Xu J, Liu X, Zhen Y. Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B. 2021;11(11):3379–3392. doi:10.1016/j.apsb.2021.03.008.
   PubMed Web of Science ®Google Scholar
• Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K, Ferbeyre G, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813–827. doi:10.1016/j.cell.2019.10.005.
   PubMed Web of Science ®Google Scholar
• Lee S, Schmitt CA. The dynamic nature of senescence in cancer. Nat Cell Biol. 2019;21(1):94–101. doi:10.1038/s41556-018-0249-2.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059.
   PubMed Web of Science ®Google Scholar
• Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 2018;28(6):436–453. doi:10.1016/j.tcb.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019;19(8):439–453. doi:10.1038/s41568-019-0156-2.
   PubMed Web of Science ®Google Scholar
• Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5(1):99–118. doi:10.1146/annurev-pathol-121808-102144.
   PubMedGoogle Scholar
• Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et al. P53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012;21(6):793–806. doi:10.1016/j.ccr.2012.04.027.
   PubMed Web of Science ®Google Scholar
• Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, Borowsky ME, Zhang R. NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer. Cancer Res. 2020;80(4):890–900. doi:10.1158/0008-5472.CAN-19-2830.
   PubMed Web of Science ®Google Scholar
• Sun X, Shi B, Zheng H, Min L, Yang J, Li X, Liao X, Huang W, Zhang M, Xu S, et al. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway. Cell Death Dis. 2018;9(3):260. doi:10.1038/s41419-018-0303-9.
   PubMed Web of Science ®Google Scholar
• Kim YH, Choi YW, Lee J, Soh EY, Kim JH, Park TJ. Senescent tumor cells lead the collective invasion in thyroid cancer. Nat Commun. 2017;8(1):15208. doi:10.1038/ncomms15208.
   PubMedGoogle Scholar
• Demaria M, O’leary MN, Chang J, Shao L, Liu S, Alimirah F, Koenig K, Le C, Mitin N, Deal AM, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7(2):165–176. doi:10.1158/2159-8290.CD-16-0241.
   PubMed Web of Science ®Google Scholar
• Ahmadinejad F, Bos T, Hu B, Britt E, Koblinski J, Souers AJ, Leverson JD, Faber AC, Gewirtz DA, Harada H. Senolytic-mediated elimination of head and neck tumor cells induced into senescence by cisplatin. Mol Pharmacol. 2022;101(3):168–180. doi:10.1124/molpharm.121.000354.
   PubMedGoogle Scholar
• Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371(6536):371. doi:10.1126/science.abc4552.
   PubMed Web of Science ®Google Scholar
• Brennan CA, Garrett WS. Fusobacterium nucleatum — symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156–166. doi:10.1038/s41579-018-0129-6.
   PubMed Web of Science ®Google Scholar
• Casasanta MA, Yoo CC, Udayasuryan B, Sanders BE, Umana A, Zhang Y, Peng H, Duncan AJ, Wang Y, Li L, et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci Signal. 2020;13(641). doi:10.1126/scisignal.aba9157.
   PubMed Web of Science ®Google Scholar
• Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, Gao R, Liu M, Yin M, Pan C, et al. Fusobacterium nucleatum Increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor−κB, and up-regulating expression of microRNA-21. Gastroenterology. 2017;152(4):851–66 e24. doi:10.1053/j.gastro.2016.11.018.
   PubMed Web of Science ®Google Scholar
• Nomoto D, Baba Y, Liu Y, Tsutsuki H, Okadome K, Harada K, Ishimoto T, Iwatsuki M, Iwagami S, Miyamoto Y, et al. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway. Cancer Lett. 2022;530:59–67. doi:10.1016/j.canlet.2022.01.014.
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–63 e16. doi:10.1016/j.cell.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Liu Y, Baba Y, Ishimoto T, Tsutsuki H, Zhang T, Nomoto D, Okadome K, Yamamura K, Harada K, Eto K, et al. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer. 2021;124(5):963–974. doi:10.1038/s41416-020-01198-5.
   PubMed Web of Science ®Google Scholar
• Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009;4(12):1798–1806. doi:10.1038/nprot.2009.191.
   PubMed Web of Science ®Google Scholar
• Hwang HJ, Lee YR, Kang D, Lee HC, Seo HR, Ryu JK, Kim Y-N, Ko Y-G, Park HJ, Lee J-S. Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells. Cancer Lett. 2020;490:100–110. doi:10.1016/j.canlet.2020.06.019.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-Cadherin/β-catenin signaling via its FadA Adhesin. Cell Host & Microbe. 2013;14(2):195–206. doi:10.1016/j.chom.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973–979. doi:10.1038/ncb1909.
   PubMed Web of Science ®Google Scholar
• Acosta JC, Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol. 2012;22(4):211–219. doi:10.1016/j.tcb.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Zhang D, Yu BP. Senescent cells in cancer therapy: why and how to remove them. Cancer Lett. 2021;520:68–79. doi:10.1016/j.canlet.2021.07.002.
   PubMed Web of Science ®Google Scholar
• Sieben CJ, Sturmlechner I, van de Sluis B, van Deursen JM. Two-step senescence-focused cancer therapies. Trends Cell Biol. 2018;28(9):723–737. doi:10.1016/j.tcb.2018.04.006.
   PubMed Web of Science ®Google Scholar
• Sikora E, Bielak-Zmijewska A, Mosieniak G. Targeting normal and cancer senescent cells as a strategy of senotherapy. Ageing Res Rev. 2019;55:100941. doi:10.1016/j.arr.2019.100941.
   PubMed Web of Science ®Google Scholar
• Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, Xi D, Zheng G, Deursen JV, Goronzy J, et al. Therapy-induced senescence: opportunities to improve anticancer therapy. J Natl Cancer Inst. 2021;113(10):1285–1298. doi:10.1093/jnci/djab064.
   PubMedGoogle Scholar
• Fletcher-Sananikone E, Kanji S, Tomimatsu N, Di Cristofaro LFM, Kollipara RK, Saha D, Floyd JR, Sung P, Hromas R, Burns TC, et al. Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res. 2021;81(23):5935–5947. doi:10.1158/0008-5472.CAN-21-0752.
   PubMed Web of Science ®Google Scholar
• Hainaut P, Pfeifer GP. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a026179. doi:10.1101/cshperspect.a026179.
   PubMed Web of Science ®Google Scholar
• Yamamura K, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, Sawayama H, Kinoshita K, Ishimoto T, Iwatsuki M, et al. Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22(22):5574–5581. doi:10.1158/1078-0432.CCR-16-1786.
   PubMed Web of Science ®Google Scholar
• Yin H, Zhang J, Zhang H, Li Q, Qiu H, Hong K, Wang W, Xiao Y, Yu B. Fusobacterium nucleatum promotes proliferation in oesophageal squamous cell carcinoma via AHR/CYP1A1 signalling. FEBS J. 2022;290(3):837–854. doi:10.1111/febs.16619.
   PubMed Web of Science ®Google Scholar
• Yamamura K, Izumi D, Kandimalla R, Sonohara F, Baba Y, Yoshida N, Kodera Y, Baba H, Goel A. Intratumoral Fusobacterium nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Clin Cancer Res. 2019;25(20):6170–6179. doi:10.1158/1078-0432.CCR-19-0318.
   PubMed Web of Science ®Google Scholar
• Liang M, Liu Y, Zhang Z, Yang H, Dai N, Zhang N, Sun W, Guo Y, Kong J, Wang X, et al. Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance. Ann Med. 2022;54(1):989–1003. doi:10.1080/07853890.2022.2061045.
   PubMed Web of Science ®Google Scholar
• Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020;34(23–24):1565–1576. doi:10.1101/gad.343129.120.
   PubMed Web of Science ®Google Scholar
• Nougayrede JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006;313(5788):848–851. doi:10.1126/science.1127059.
   PubMed Web of Science ®Google Scholar
• Zanzoni A, Spinelli L, Braham S, Brun C. Perturbed human sub-networks by Fusobacterium nucleatum candidate virulence proteins. Microbiome. 2017;5(1):89. doi:10.1186/s40168-017-0307-1.
   PubMedGoogle Scholar
• Sanders BE, Umana A, Lemkul JA, Slade DJ. Erratum for sanders et al., “FusoPortal: an interactive repository of hybrid MinION-Sequenced Fusobacterium genomes improves gene identification and characterization”. mSphere. 2018 ;3(4). doi:10.1128/mSphere.00379-18.
   Web of Science ®Google Scholar
• Guo P, Tian Z, Kong X, Yang L, Shan X, Dong B, Ding X, Jing X, Jiang C, Jiang N, et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J Exp Clin Cancer Res. 2020;39(1):202. doi:10.1186/s13046-020-01677-w.
   PubMed Web of Science ®Google Scholar
• Teillant A, Gandra S, Barter D, Morgan DJ, Laxminarayan R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis. 2015;15(12):1429–1437. doi:10.1016/S1473-3099(15)00270-4.
   PubMed Web of Science ®Google Scholar
• Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156–1160. doi:10.1126/science.aah5043.
   PubMed Web of Science ®Google Scholar
• Imai H, Saijo K, Komine K, Otsuki Y, Ohuchi K, Sato Y, Okita A, Takahashi M, Takahashi S, Shirota H, et al. Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study. cancer Manag Res. 2019;11:7953–7965. doi:10.2147/CMAR.S215697.
   PubMed Web of Science ®Google Scholar
• Nakano S, Komatsu Y, Kawamoto Y, Saito R, Ito K, Nakatsumi H, Yuki S, Sakamoto N. Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Medi (Baltimore). 2020;99(39):e22250. doi:10.1097/MD.0000000000022250.
   PubMed Web of Science ®Google Scholar
• Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, et al. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021;10(15):5041–5050. doi:10.1002/cam4.3870.
   PubMed Web of Science ®Google Scholar
• Ting NL, Lau HC, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut. 2022;71(7):1412–1425. doi:10.1136/gutjnl-2021-326264.
   PubMed Web of Science ®Google Scholar
• Liu L, Shah K. The potential of the gut microbiome to reshape the cancer therapy paradigm: a review. JAMA Oncol. 2022;8(7):1059. doi:10.1001/jamaoncol.2022.0494.
   PubMed Web of Science ®Google Scholar
• Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nat Med. 2022;28(4):690–703. doi:10.1038/s41591-022-01779-2.
   PubMed Web of Science ®Google Scholar
• Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, et al. Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc Natl Acad Sci U S A. 2022;119(5):119. doi:10.1073/pnas.2117754119.
   Web of Science ®Google Scholar
• Kong C, Yan X, Zhu Y, Zhu H, Luo Y, Liu P, Ferrandon S, Kalady MF, Gao R, He J, et al. Fusobacterium nucleatum promotes the development of colorectal cancer by activating a Cytochrome P450/Epoxyoctadecenoic acid axis via TLR4/Keap1/NRF2 signaling. Cancer Res. 2021;81(17):4485–4498. doi:10.1158/0008-5472.CAN-21-0453.
   PubMed Web of Science ®Google Scholar